Open-Label Study Evaluating Synera® in the Treatment of Patients With Carpal Tunnel Syndrome

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to explore the potential usefulness of Synera for the treatment of pain associated with mild to moderate carpal tunnel syndrome.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ZARS Pharma Inc.
• Treatments: Lidocaine; Tetracaine

Criteria

Inclusion Criteria:

• Pain associated with mild to moderate carpal tunnel syndrome in a single wrist

• Have recent (within 3 months) electrodiagnostic evidence of carpal tunnel syndrome (CTS)

Exclusion Criteria:

• Have bilateral carpal tunnel syndrome

• Have another peripheral neuropathy in the affected limb

• Have had an injection into the carpal tunnel within 8 weeks

• Have had surgical release of the target wrist within previous 6 months

• Have electrodiagnostic evidence of severe CTS

Other protocol-defined inclusion/exclusion criteria may apply